IMS Health — Merger or Acquisition (May 2016)
13 slides from IMS Health's merger presentation, May 17, 2016
Slide 1: Drug Development Closing the Loop
Drug Development Closing the Loop May 17th 2016
Slide 2: Cautionary Statements Regarding Forward Looking Statements
Cautionary Statements Regarding Forward Looking Statements This communication contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Slide 3: Important Information About the Transaction and Where to Find It
Important Information About the Transaction and Where to Find It In connection with the proposed transaction, IMS Health and Quintiles will be filing documents with the Securities and Exchange Commission (“SEC”), including the filing by Quintiles of a registration statement on Form S-4, and Quintile
Slide 4: Components of developing new therapies
Discovery Pre-clinical and toxicology Phase 1 (IND) Phase 2 Phase 3 New Drug Application (NDA) Market Access/ Payer Marketing and commercial launch Payer Real World Components of developing new therapies
Slide 5: Bio-pharma recovering from a recent productivity lull
Bio-pharma recovering from a recent productivity lull CDER FDA approvals 1999-2015 Phase 3 failures 2007-2010 IMS Health Informatics US use of medications Apr 2014 FDA reports 2015 Nature Reviews Drug Discovery.2011:10:87 (February 2011) Breakthrough Designation *BLAs transferred to CDER *
Slide 6: Impact of more targeted therapies and patient populations
Impact of more targeted therapies and patient populations Increased probability of success of more targeted therapies alone and combined with companion diagnostics (CDx) J Thorac Oncol. 2014;9:163–169 Cumulative success rate of new therapies for NSCLC 1998-2012
Slide 7: Biomarkers for stratification and treatment optimization
Biomarkers for stratification and treatment optimization Ongoing transition from anatomic pathology to genomic sequencing PMC Coalition Progress Report 2014 PMC Coalition Progress Report 2015 Tufts CSDD Personalized Medicine Is Playing a Growing Role in Development Pipelines 2010
Slide 8: Shift towards novel therapies and smaller indications
Shift towards novel therapies and smaller indications An evolving definition of a “rare” disease IMS Health Informatics US use of medications Apr 2014 FDA reports 2015
Slide 9: Even in smaller populations, blockbusters are possible
Even in smaller populations, blockbusters are possible Novel therapies, even in small populations, can potentially generate significant revenue Trends in US NDAs HBM Partners, 2016
Slide 10: Increasing Complexity of Clinical Studies
Increasing Complexity of Clinical Studies Consequence of therapies designed for stratified populations, rate indications with targeted therapies and biomarkers Design Characteristics 2002 2012 % Change Total Number of Endpoint 7 13 86% # Total Number of Procedures 106 167 58% # Total Number of Eligi
Slide 11: Definition of success in drug development - The Past
Discovery Pre-clinical and toxicology Phase 1 (IND) Phase 2 Phase 3 Market Authorization (NDA) Definition of success in drug development - The Past Goal: successful market authorization- new drug application (NDA) Past
Slide 12: Definition of success in drug development - The Present
Definition of success in drug development - The Present Goal: obtain reimbursement, market-access with some pharmacoeconomic validation or safety surveillance Past Present Discovery Pre-clinical and toxicology Phase 1 (IND) Phase 2 Phase 3 Market Authorization (NDA) Market Access / Payer Marketing a
Slide 13: Definition of success in drug development - The Future
Definition of success in drug development - The Future Goal: utilize the full spectrum of data to inform future discovery and clinical development Past Present Future Discovery Pre-clinical and toxicology Phase 1 (IND) Phase 2 Phase 3 Market Authorization (NDA) Market Access / Payer Marketing and co
IMS Health Holdings — Merger or Acquisition (May 2016) on 6ix